Moleculin Receives Approval for Leukemia Clinical Trial

Pharmaceutical Investing

Moleculin Biotech (NASDAQ:MBRX) has announced it has received Polish National Office approval to begin its second Phase I/II clinical trial to study Annamycin for treatment of relapsed or refactory acute myeloid leukemia. As quoted in the press release: “This approval is a significant step forward to be able to treat additional patients with AML and …

As quoted in the press release:

“This approval is a significant step forward to be able to treat additional patients with AML and to generate positive clinical data regarding Annamycin,” commented Walter Klemp, Chairman and CEO of Moleculin. “Consent from the Polish National Office was the final step required to allow us to begin recruiting patients for this important trial. Enrollment will begin immediately and we expect patients to commence receiving treatment, at the appropriate dose, in this clinical trial during the second half of this year.”

Click here to read the full press release.

Pharmaceutical Investing